Drugs / Racotumomab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01598454 | Feb 2011 → Mar 2014 | Ewing sarcoma, Wilms tumor, glioma, neuroblastoma +1 | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02998983 | Nov 2016 → Nov 2022 | neuroblastoma | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 2 | NCT01240447 | Sep 2009 → Aug 2012 | non-small cell lung carcinoma | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01460472 | Sep 2010 → Sep 2016 | non-small cell lung carcinoma | Recombio SL | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | racotumomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01598454 ↗ |
| Modality | Vaccine | “vaccination with racotumomab” NCT01240447 ↗ |
| Route | Other | “Drug dose was escalated to three levels (0.15-0.25-0.4 mg) of racotumomab administered intradermally.” PMID 26154941 ↗ Jul 2015 |